Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries
Objective: Assess the cost effectiveness of budesonide/formoterol (BUD/FORM) Turbuhaler (R) +tiotropium (TIO) HandiHaler (R) vs. placebo (PBO)+TIO in patients with chronic obstructive pulmonary disease (COPD) eligible for inhaled corticosteroids/long-acting beta(2)-agonists (ICS/LABA). Methods: The cost-effectiveness analysis was based on the 12-week, randomised, double-blind CLIMB trial. The stud